Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 6/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.39 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2942958 | 0.80 | TP53 (0.47) | MAPTRAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL2942959 | 0.80 | TP53 (0.47) | MAPTRAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL23213140 | 0.80 | ALDH1A1 (0.48) | MAPTRAB9ANPC1SMN1; SMN2ALOX5 | |
| SCHEMBL29796135 | 0.80 | ALDH1A1 (0.48) | MAPTRAB9ANPC1SMN1; SMN2ALOX5 | |
| SCHEMBL2645099 | 0.80 | HSP90AA1 (0.43) | HSP90AA1HSP90AB1MAPTRAB9ANPC1 | |
| SCHEMBL30918979 | 0.80 | HSP90AA1 (0.49) | HSP90AA1HSP90AB1MEN1KMT2APIK3R1 | |
| SCHEMBL978142 | 0.80 | HSP90AA1 (0.55) | HSP90AA1HSP90AB1MAPTRAB9ANPC1 | |
| SCHEMBL31226734 | 0.80 | ALDH1A1 (0.45) | MAPTRAB9ANPC1SMN1; SMN2ALOX5 | |
| SCHEMBL21296822 | 0.79 | ALDH1A1 (0.44) | MAPTRAB9ANPC1SMN1; SMN2ALOX5 | |
| SCHEMBL12450000 | 0.79 | HSP90AA1 (0.52) | HSP90AA1HSP90AB1PIK3R1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709712-A1 | GSK3A INHIBITORS AND METHODS OF USE THEREOF | Blueprint Medicines Corporation (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12358869-B2 | Diarylureas as CB1 allosteric modulators | RESEARCH TRIANGLE INSTITUTE | 2025-07-15 | — | — | US | disclosed |
| WO-2024233900-A1 | GSK3A INHIBITORS AND METHODS OF USE THEREOF | BLUEPRINT MEDICINES CORPORATION (US) | 2024-11-14 | — | — | WO | disclosed |
| CN-116283668-A | Diaryl ureas as CB1 allosteric modulators | 研究三角协会 | 2023-06-23 | — | — | CN | disclosed |
| CN-110621656-A | Diaryl ureas as CB1 allosteric modulators | 研究三角协会 | 2019-12-27 | — | — | CN | disclosed |
| US-7622585-B2 | Phenylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-11-24 | — | — | US | disclosed |
| EP-1490367-B1 | IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2008-07-23 | — | — | EP | disclosed |
| US-7348339-B2 | 2-(4-amino-furazan-3-yl)-1-ethyl-N-[(2R)-2-morpholinylmethyl]-1H-imidazo[4,5-c]pyridine-7-carboxamide; Mitogen- and Stress-Activated Protein (MSK) and Rho (guanosine triphosphate) 1 or 2 kinase inhibitor; neurodegenerative diaeases; antiinflammatory, anticarcinogenic, antiviral and antibacterial agent | GLAXO GROUP LIMITED (GB) | 2008-03-25 | — | — | US | disclosed |
| US-20050197328-A1 | Imidazopyridine derivatives as kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12358869-B2 | Diarylureas as CB1 allosteric modulators | CNR1, CNR2, GPR18 | HSP90AA1 4045/4885HSP90AB1 3841/4885MAPT 2523/4885 |
| US-20050197328-A1 | Imidazopyridine derivatives as kinase inhibitors | NR4A3, XDH, MAPK8 | HSP90AA1 4549/4885HSP90AB1 4292/4885MAPT 4618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.